Author:
Daneshmand Siamak,Schuckman Anne K.,Bochner Bernard H.,Cookson Michael S.,Downs Tracy M.,Gomella Leonard G.,Grossman H. Barton,Kamat Ashish M.,Konety Badrinath R.,Lee Cheryl T.,Pohar Kamal S.,Pruthi Raj S.,Resnick Matthew J.,Smith Norm D.,Witjes J. Alfred,Schoenberg Mark P.,Steinberg Gary D.
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Bladder Cancer [online], (2014).
2. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–477 (2006).
3. Babjuk, M. et al. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology [online], (2013).
4. Hall, M. C. et al. Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007).
5. James, A. C. & Gore, J. L. The costs of non-muscle invasive bladder cancer. Urol. Clin. North Am. 40, 261–269 (2013).
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献